Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients
In high-risk ambulatory patients with cancer, the incidence of venous thromboembolism or death due to venous thromboembolism during 180 days is not significantly reduced for rivaroxaban compared with placebo.